Celgene Corporation exists to discover, develop and deliver innovative medicines that can improve and extend patients’ lives worldwide. It is our purpose and our mission.
In the 14 years I have been a part of Celgene, I’ve had the privilege of seeing our organization produce transformational medicines that are helping hundreds of thousands of patients. During that time, Celgene has grown from an early-stage start-up to a global company with more than 8,500 employees, eight marketed products and a research engine with nearly 160 ongoing clinical trials and 30 novel agents in development across 40 indications.
As we strive to achieve our mission, we continue to focus on meeting the expectations of all stakeholders. This year’s corporate responsibility report highlights how Celgene and its employees are working to make a difference in the lives of patients, communities and economies around the world.
We are at a very important time in our company’s journey to help patients and create increased value for our stockholders. Over the next two years, we expect to advance five late-stage products toward regulatory approval — fedratinib, luspatercept, ozanimod, liso-cel and bb2121. These therapies represent the promise of our industry-leading investments in research, and the beginning of our next wave of innovation that is delivering multiple new product candidates expected to enter mid-stage clinical development during this same period.
Our work to discover and develop these therapies is meaningless if patients cannot access them. As a result, patient access is a vital part of our mission and central to our efforts. For patients being treated with Celgene medicines in the U.S., we have and will continue to offer co-pay assistance for eligible commercially insured patients and free product for qualified patients who are uninsured or underinsured, are unable to afford their medication, and meet other criteria.
To help address patients’ medical needs in low- and middle-income countries, Celgene is a member of Access Accelerated, a partnership of 24 biopharmaceutical companies developing innovative and sustainable solutions to improve access to treatment and care for non-communicable diseases, including cancer. In the first year of this program, 62 company programs operating in 88 countries are contributing to the mission of Access Accelerated.
To that end, we are working with the Academic Model Providing Access to Healthcare (AMPATH) program in partnership with the Government of Kenya to deliver healthcare services and strengthen health system capacity around important health-related initiatives. This program includes multiple myeloma care, pharmacovigilance, patient education and pharmacy residency programs.
We also recently introduced Celgene Cancer Care Links?, a grant program designed to support cancer healthcare capacity through partnerships in resource-constrained countries. This adds to our continued efforts to support health-related philanthropic programs, science education, and local community activities for Celgene sites and affiliates around the world.
I am extremely proud of the work we do on behalf of patients with serious unmet medical needs and by Celgene’s dedicated and diverse workforce. Our employees embody a remarkable culture at Celgene that was recently recognized by Forbes as one of the World’s Best Employers, ranking 9th out of the 2,000 largest companies worldwide. In 2018, we took steps to further enhance this standing as we expanded the benefits provided to our employees — such as flexible work arrangements and increased paid parental leave for our U.S. employees. We recognize and appreciate how vital our employees are to the patients we seek to serve and are continually seeking to further strengthen our culture and engagement.
To help ensure a sustainable future and a healthy environment, we have become a member of the Environmental Protection Agency’s Green Power Partnership, which recognizes companies committed to using renewable energy sources. Today, 73 percent of our electricity for U.S. office facilities is derived from renewable energy sources. We continue to advance toward our 2020 environmental goals to reduce emissions, increase purchasing of renewable energy, decrease water withdrawal and decrease solid waste generation. We achieved LEED? certification this year for the recently remodeled Conference Center and office building on our main campus. This follows the successful certification last year of our main campus expansion.
As part of our focus on business with integrity, we joined the Pharmaceutical Supply Chain Initiative in 2018. This group of major healthcare companies is working to establish and promote responsible practices that will improve social, health, safety and environmental sustainability outcomes for biopharmaceutical company supply chains. Additionally, Celgene ranked in the top five for Clinical Trial Transparency by the Bioethics International Good Pharma Scorecard.
Through our efforts across these critical areas, we continue to meet our responsibilities to stakeholders, remaining focused on our mission to improve patients’ lives, while applying the highest standards of ethics, integrity and purpose.
We remain steadfastly committed to our mission, as we work to discover, develop and deliver to patients new and even more effective ways to improve and extend the lives of patients around the world.
MARK J. ALLES
Chairman and Chief Executive Officer